RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 4, 2015, Pages 1639-1645

  Chen, Kong Y ^a   Muniyappa, Ranganath ^a   Abel, Brent S ^a   Mullins, Katherine P ^a   Staker, Pamela ^a   Brychta, Robert J ^a   Zhao, Xiongce ^a   Ring, Michael ^a   Psota, Tricia L ^a   Cone, Roger D ^b   Panaro, Brandon L ^b   Gottesdiener, Keith M ^c   Van Der Ploeg, Lex H T ^c   Reitman, Marc L ^a   Skarulis, Monica C ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Rhythm Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SETMELANOTIDE; ALPHA INTERMEDIN; ANTIOBESITY AGENT; BIM-22493; MELANOCORTIN 4 RECEPTOR;

ADULT; ARTHRALGIA; ARTICLE; BODY MASS; CALORIMETER; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXERCISE; FEMALE; HEADACHE; HUMAN; MALE; MORNING DOSAGE; NAUSEA; OBESITY; PENIS ERECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY QUOTIENT; RESTING ENERGY EXPENDITURE; SHORT COURSE THERAPY; SIDE EFFECT; TEST MEAL; AGONISTS; ANALOGS AND DERIVATIVES; DRUG EFFECTS; ENERGY METABOLISM; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; REST; WEIGHT LOSS PROGRAM; YOUNG ADULT;

PRIMATES;

ADULT; ALPHA-MSH; ANTI-OBESITY AGENTS; COMBINED MODALITY THERAPY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENERGY METABOLISM; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; RECEPTOR, MELANOCORTIN, TYPE 4; REST; WEIGHT REDUCTION PROGRAMS; YOUNG ADULT;

EID: 84927618698     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-4024     Document Type: Article

References (29)

1. Cone RD. The central melanocortin system and energy homeostasis. Trends Endocrinol Metab. 1999;10:211-216.
2. Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27:736-749.
3. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997;385:165-168.
4. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest. 2000;106:253-262.
5. Krakoff J, Ma L, Kobes S, et al. Lower metabolic rate in individuals heterozygous for either a frameshift or a functional missense MC4R variant. Diabetes. 2008;57:3267-3272.
6. Hinney A, Volckmar AL, Knoll N. Melanocortin-4 receptor in energy homeostasis and obesity pathogenesis. Prog Mol Biol Transl Sci. 2013;114:147-191.
7. Fani L, Bak S, Delhanty P, van Rossum EF, van den Akker EL. The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options. Int J Obes (Lond). 2014;38:163-169.
8. Tao YX. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev. 2010;31:506-543.
9. Kievit P, Halem H, Marks DL, et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes. 2013;62:490-497.
10. Schutz Y, Jequier E. Resting Energy Expenditure, Thermic Effect of Food and Total Energy Expenditure. New York, NY: Marcel Dekker; 1998.
11. Rumpler WV, Seale JL, Conway JM, Moe PW. Repeatability of 24-h energy expenditure measurements in humans by indirect calorimetry. Am J Clin Nutr. 1990;51:147-152.
12. Ravussin E, Lillioja S, Anderson TE, Christin L, Bogardus C. Determinants of 24-hour energy expenditure in man. Methods and results using a respiratory chamber. J Clin Invest. 1986;78:1568-1578.
13. Cooper JA, Watras AC, O'Brien MJ, et al. Assessing validity and reliability of resting metabolic rate in six gas analysis systems. J Am Diet Assoc. 2009;109:128-132.
14. Greenfield JR, Miller JW, Keogh JM, et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med. 2009;360:44-52.
15. Hwa JJ, Ghibaudi L, Gao J, Parker EM. Central melanocortin system modulates energy intake and expenditure of obese and lean Zucker rats. Am J Physiol Regul Integr Comp Physiol. 2001;281:R444-R451.
16. Cowley MA, Pronchuk N, Fan W, Dinulescu DM, Colmers WF, Cone RD. Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat. Neuron. 1999;24:155-163.
17. Hsiung HM, Hertel J, Zhang XY, et al. A novel and selective betamelanocytestimulating hormone-derived peptide agonist for melanocortin 4 receptor potently decreased food intake and body weight gain in diet-induced obese rats. Endocrinology. 2005;146:5257-5266.
18. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. Thermogenic effects of sibutramine in humans. Am J Clin Nutr. 1998;68:1180-1186.
19. Astrup A, Toubro S, Cannon S, Hein P, Breum L, Madsen J. Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers. Am J Clin Nutr. 1990;51:759-767.
20. Butler AA, Marks DL, Fan W, Kuhn CM, Bartolome M, Cone RD. Melanocortin-4 receptor is required for acute homeostatic responses to increased dietary fat. Nat Neurosci. 2001;4:605-611.
21. Zurlo F, Lillioja S, Esposito-Del Puente A, et al. Low ratio of fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ. Am J Physiol. 1990;259:E650-E657.
22. Fan W, Dinulescu DM, Butler AA, Zhou J, Marks DL, Cone RD. The central melanocortin system can directly regulate serum insulin levels. Endocrinology. 2000;141:3072-3079.
23. Tanaka T, Masuzaki H, Yasue S, et al. Central melanocortin signaling restores skeletal muscle AMP-activated protein kinase phosphorylation in mice fed a high-fat diet. Cell Metab. 2007;5:395-402.
24. Heijboer AC, van den Hoek AM, Pijl H, et al. Intracerebroventricular administration of melanotan II increases insulin sensitivity of glucose disposal in mice. Diabetologia. 2005;48:1621-1626.
25. Harris M, Aschkenasi C, Elias CF, et al. Transcriptional regulation of the thyrotropin-releasing hormone gene by leptin and melanocortin signaling. J Clin Invest. 2001;107:111-120.
26. Panaro BL, Tough IR, Engelstoft MS, et al. 2014 The melanocortin-4 receptor is expressed in enteroendocrine L cells and regulates the release of peptide YY and glucagon-like peptide 1 in vivo. Cell Metab. 2014;20:1018-1029.
27. Royalty JE, Konradsen G, Eskerod O, Wulff BS, Hansen BS. Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting β-MSH analog in healthy overweight and obese subjects. J Clin Pharmacol. 2014;54:394-404.
28. Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. J Sex Med. 2008;5:887-897.
29. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Doubleblind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16:51-59.